Financial Performance - The company's operating revenue for 2024 was ¥10,701,990,901.10, a decrease of 1.76% compared to ¥10,893,535,007.49 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥282,237,728.37, down 44.18% from ¥505,621,135.98 in 2023[6]. - The net profit after deducting non-recurring gains and losses was ¥252,253,354.61, a decline of 45.52% from ¥463,047,159.03 in 2023[6]. - The net cash flow from operating activities decreased by 17.88% to ¥1,661,734,794.26 from ¥2,023,559,606.53 in 2023[6]. - The basic earnings per share for 2024 was ¥0.07, a decrease of 46.15% compared to ¥0.13 in 2023[6]. - Total revenue for 2024 was ¥10,701,990,901.10, a decrease of 1.76% compared to ¥10,893,535,007.49 in 2023[84]. - Revenue from the healthcare sector was ¥10,656,768,719.39, accounting for 99.58% of total revenue, with a year-on-year decrease of 1.96%[84]. - The gross margin for the healthcare sector was 42.76%, slightly improved by 0.05% from the previous year[85]. Business Transformation and Strategy - The company has undergone a significant business transformation since 2015, shifting from garment manufacturing to primarily focusing on professional health examination services[15]. - The company is focusing on expanding health check-up services and enhancing personalized health management capabilities in response to government policies promoting health consumption[26]. - The company aims to transition from single health check-up services to comprehensive health management, establishing a new model of "check-up in 2 hours, service for 365 days"[39]. - The company is actively developing AI-driven health management products to meet the increasing demand for personalized and intelligent health services[39]. - The company is focused on expanding its digital health service platform, enhancing customer experience through AI-driven personalized health management solutions[48]. - The company is committed to enhancing its service quality and operational efficiency through standardized medical management and advanced technology integration[42]. Market Trends and Projections - The health management market in China is projected to reach a total revenue of 9 trillion yuan by 2024, with a compound annual growth rate (CAGR) of 12.5% from 2023 to 2028[32]. - The health check-up market size in China was 190.4 billion yuan in 2022, reflecting a year-on-year growth of approximately 10.7%[32]. - By 2025, the health check-up market is expected to expand to 390 billion yuan[32]. - The per capita healthcare expenditure in China is forecasted to be 2,547 yuan in 2024, representing a year-on-year increase of 3.6%[33]. - The elderly population (aged 60 and above) in China is projected to exceed 310 million by the end of 2024, accounting for 22% of the total population[35]. Technology and Innovation - The company is focusing on high-quality professional health check-up services, leveraging big data and AI technology to enhance customer experience and service offerings[38]. - AI technology is widely applied in various diagnostic areas, including lung nodule diagnosis, stroke risk assessment, and breast ultrasound AI diagnosis[47]. - The company has established the largest personal health check-up data center in China, with over 1 billion imaging data and more than 200 million structured health data points[46]. - The company has implemented an "All in AI" strategy, promoting AI-driven products such as "AI Smart Blood Sugar Management" and "Health Xiao Mei" to enhance customer satisfaction and repurchase rates[51]. Customer Engagement and Experience - The company received a total of 25.25 million visits in 2024, with 15.38 million visits from wholly-owned examination branches, and the revenue share from group and individual clients was 75.9% and 24.1% respectively[54]. - The average customer price for health examinations in 2024 was 672 RMB, continuing to show stable growth[54]. - The customer management center has focused on improving customer experience, achieving significant results in enhancing customer NPS values through refined operational management[59]. - The company has optimized its customer structure through a focus on high-value corporate clients, achieving significant improvements in the B-end business segment[62]. Governance and Compliance - The company has a governance structure that complies with relevant laws and regulations, ensuring fair treatment of all shareholders, especially minority shareholders[145]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[146]. - The company has established a fair and transparent performance evaluation system for directors and senior management, ensuring compliance with legal regulations and effective governance[147]. - The company has implemented a robust internal audit system to monitor compliance and the execution of internal controls, enhancing risk management[149]. Human Resources and Training - The total number of employees at the end of the reporting period was 38,253, with 22 from the parent company and 38,231 from major subsidiaries[188]. - The company implemented a compensation policy based on "position, ability, and performance," aligning with market levels to ensure fairness and motivation among employees[189]. - A total of 1,913 training contents were launched throughout the year, with 15.18 million total learning instances and over 310,000 total learning hours[192]. - The company introduced a "credit incentive system" to boost employee engagement in learning, resulting in a 35% increase in participation[192]. Future Outlook and Plans - The company plans to enhance personalized health management services, including specialized examinations and post-examination management packages[122]. - The company aims to strengthen its product capabilities through continuous innovation, targeting key areas such as ultrasound intelligence and AI-assisted diagnosis, with a focus on personalized health management solutions[126]. - The company plans to deepen its exploration of innovative operational models, establishing a comprehensive online and offline operational system to drive revenue growth from new products[127]. - The company aims for "comprehensive efficiency and leapfrog growth" by 2025, focusing on organizational transformation and lean operations to enhance marketing and medical center efficiencies[135].

证券代码：002044 证券简称：美年健康 公告编号：2025-014 美年大健康产业控股股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、审议程序 美年大健康产业控股股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日 召开了第九届董事会第八次会议，以 9 票同意，0 票反对，0 票弃权审议通过了 《关于 2024 年度利润分配预案的议案》。同日，公司召开第八届监事会第二十九 次会议，以 3 票同意，0 票反对，0 票弃权审议通过了《关于 2024 年度利润分配 预案的议案》。 本次利润分配预案尚需提交公司 2024 年度股东大会审议。 二、公司 2024 年度利润分配预案的基本情况 （一）公司不存在可能触及其他风险警示情形 项目 2024 年度 2023 年度 2022 年度 现金分红总额（元） 52,842,427.96 74,370,807.50 0 回购注销总额（元） 0 0 0 归属于上市公司股东的净利润（元） 282,237,728.37 505,621,135.98 -559 ...

美年健康（002044）公告，2024年营业收入为107.02亿元，同比下降1.76%。归属于上市公司股东的净 利润为2.82亿元，同比下降44.18%。公司拟向全体股东每10股派发现金红利0.135元(含税)，送红股0股 (含税)，不以公积金转增股本。 ...

4月16日，美年健康今日收盘5.33元，下跌2.38%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到67.93倍，总市值208.63亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均45.05倍，行业中值46.97倍，美年健康排 名第34位。 资金流向方面，4月16日，美年健康主力资金净流出3704.23万元，近5日总体呈流入状态，5日共流入 2436.31万元。 美年大健康产业控股股份有限公司主营业务为健康体检服务。公司主要提供的服务为体检服务。公司是 体检行业的龙头企业，公司是国内规模领先、分布最广的专业体检及医疗机构，旗下拥有四大品牌"美 年大健康"、"慈铭"、"慈铭奥亚"、"美兆"。 最新一期业绩显示，2024年三季报，公司实现营业收入71.41亿元，同比-1.96%；净利润2463.25万元， 同比-88.96%，销售毛利率39.67%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)34美年健康67.9341.262.73208.63亿行业平均 45.0541.013.36141.40亿行业中值46.9735.682.4248.61亿1普瑞眼科-185.6423 ...

事件： 4 月14 日晚，美年健康发布公告，拟通过发行股份的方式购买交易对方持有的衡阳美年84.00% 股权、宁德美年81.00%股权、烟台美年75.00%股权、烟台美年福田49.00%股权、武汉奥亚52.81%股 权、三明美年85.00%股权、肥城美年90.00%股权、南宁美元康69.86%股权、德州美年84.00%股权、安 溪美年72.90%股权、连江美年82.00%股权、沂水美年80.50% 股权、山东奥亚92.35%股权、厦门银城美 年 81.00%股权及控股子公司郑州美健47.37%少数股权、花都美年49.00%少数股权、安徽美欣42.46%少 数股权、淄博美年49.00%少数股权、吉林昌邑美年48.05% 少数股权。合计19 家体检机构，此次交易完 成后，上市公司将直接及间接持有包括衡阳美年在内的18 家体检机构100.00%及安溪美年90.00%股权。 由于标的公司的审计、评估工作尚未完成，本次交易的具体交易价格尚未确定。 盈利预测与估值：由于收购的机构经营业绩尚未审计，并表时间也尚不明确，暂不调整上市公司盈利预 测。公司2024-2026 年营业收入预期分别为105.99、116.14、127 ...

医药生物 上 市 公 司 2025 年 04 月 15 日 美年健康 (002044) ——拟购买 19 家体检机构股权，发行股份助力规模扩张 报告原因：有信息公布需要点评 买入（维持） | 市场数据： | 2025 年 04 月 14 日 | | --- | --- | | 收盘价（元） | 5.51 | | 一年内最高/最低（元） | 7.79/3.22 | | 市净率 | 2.8 | | 股息率%（分红/股价） | 0.34 | | 流通 A 股市值（百万元） | 21,337 | | 上证指数/深证成指 | 3,262.81/9,884.30 | 注："股息率"以最近一年已公布分红计算 | 基础数据: | 2024 年 09 月 30 日 | | --- | --- | | 每股净资产（元） | 1.96 | | 资产负债率% | 55.68 | | 总股本/流通 A 股（百万） | 3,914/3,872 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 04-15 05-15 06-15 07-15 08-15 09-15 10-15 11-15 12-15 01- ...

中国经济网北京4月15日讯美年健康（002044）(002044.SZ)昨日晚间披露《发行股份购买资产暨关联交 易预案》。 美年健康拟通过发行股份的方式购买交易对方持有的衡阳美年健康体检中心有限公司(简称：衡阳美 年)84.00%股权、宁德美年大健康管理有限公司(简称：宁德美年)81.00%股权、烟台美年大健康体检管 理有限公司(简称：烟台美年)75.00%股权、烟台美年福田健康体检管理有限公司(简称：烟台美年福 田)49.00%股权、武汉美慈奥亚科技管理有限公司(简称：武汉奥亚)52.81%股权、三明美年大健康管理 有限公司(简称：三明美年)85.00%股权、肥城美年健康管理有限公司(简称：肥城美年)90.00%股权、南 宁美元康健康管理有限公司(简称：南宁美元康)69.86%股权、德州美年大健康体检管理有限公司(简 称：德州美年)84.00%股权、安溪美年大健康管理有限公司(简称：安溪美年)72.90%股权、连江美年大 健康管理有限公司(简称：连江美年)82.00%股权、沂水美年大健康体检管理有限公司(简称：沂水美 年)80.50%股权、山东美铭奥亚健康咨询有限公司(简称：山东奥亚)92.35%股权、厦门 ...

4月14日晚，美年健康（002044.SZ）发布公告，公司拟通过发行股份的方式购买19家上市公司参股或控股的体检中 心，包括衡阳美年等14家公司股权及郑州美健等5家控股子公司的少数股权。公司表示，本次交易属于公司原有业务 的扩展，有利于上市公司产业结构的优化调整，扩大公司业务规模以及增强区域协同效应，提高市场占有率，持续提 升盈利能力与增强综合竞争力。 聚焦主业高质量发展的同时，美年健康多措并举加速布局健康管理赛道，发展个性化健康管理产品推介、减重代谢等 领域，通过AI与大数据持续赋能，开拓健康管理新蓝海。 海通证券研报认为，美年健康充分发挥预防医学龙头企业的价值，包括规模效应、数据资产、多元化场景和20年的行 业Knowhow积累，充分抓住AI+医疗爆发的市场机遇，利用大模型技术驱动，从低频单一的年度体检服务升级成动态 持续的健康管家，降低个性化医疗、主动健康服务的边际成本，做到医疗普惠，持续强化AI人工智能技术与医疗服务 领域的深度赋能与创新应用，持续提升服务效率和客户体验满意度，构建"体检两小时，服务365天"的健管新业态，打 造"健康中国"在AI时代的美年标杆。 AI赋能个性化健康管理 近日，"202 ...

格隆汇4月14日丨美年健康(002044.SZ)公布发行股份购买资产暨关联交易预案，美年健康拟通过发行股 份的方式购买交易对方持有的衡阳美年84.00%股权、宁德美年81.00%股权、烟台美年75.00%股权、烟 台美年福田49.00%股权、武汉奥亚52.81%股权、三明美年85.00%股权、肥城美年90.00%股权、南宁美 元康69.86%股权、德州美年84.00%股权、安溪美年72.90%股权、连江美年82.00%股权、沂水美年 80.50%股权、山东奥亚92.35%股权、厦门银城美年81.00%股权及控股子公司郑州美健47.37%少数股 权、花都美年49.00%少数股权、安徽美欣42.46%少数股权、淄博美年49.00%少数股权、吉林昌邑美年 48.05%少数股权。 本次交易上市公司拟收购多家标的公司股权，标的公司均为上市公司参股或控股的体检中心，主营业务 为提供健康体检服务，本次交易属于公司原有业务的扩展，有利于上市公司产业结构的优化调整，扩大 公司业务规模以及增强区域协同效应，提高市场占有率，提升经营能力、综合竞争力和抗风险能力，解 决同业竞争，减少关联交易。 本次交易完成后，上市公司在健康体检服务 ...

美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）拟通过 发行股份的方式购买交易对方持有的衡阳美年健康体检中心有限公司 84.00%股 权、宁德美年大健康管理有限公司 81.00%股权、烟台美年大健康体检管理有限 公司 75.00%股权、烟台美年福田健康体检管理有限公司 49.00%股权、武汉美慈 奥亚科技管理有限公司 52.81%股权、三明美年大健康管理有限公司 85.00%股权、 肥城美年健康管理有限公司 90.00%股权、南宁美元康健康管理有限公司 69.86% 股权、德州美年大健康体检管理有限公司 84.00%股权、安溪美年大健康管理有 限公司 72.90%股权、连江美年大健康管理有限公司 82.00%股权、沂水美年大健 康体检管理有限公司 80.50%股权、山东美铭奥亚健康咨询有限公司 92.35%股权、 厦门银城美年大健康管理有限公司 81.00%股权及控股子公司郑州美健健康管理 有限公司 47.37%少数股权、广州花都区美年大健康管理有限公司 49.00%少数股 权、安徽美欣健康管理咨询有限公司 42.46%少数股权、淄博美年大健康管理有 限公司 49.00%少数股权、吉林市昌邑区 ...